Echocardiography Guided TAVR (Echo TAVR)

Launched by PAN XIANGBIN · Jun 12, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a new way to perform a procedure called transcatheter aortic valve replacement (TAVR), which is used to treat severe narrowing of the aortic valve in the heart. Normally, TAVR uses X-rays and special dye (contrast agents) to guide the procedure, but these can be risky for some patients, especially those with kidney problems or a history of cancer. This study is testing whether using ultrasound imaging (echocardiography) instead can be a safer and effective alternative to guide the valve replacement without the need for radiation or dye.

People who might be eligible for this trial include adults with severe symptoms caused by a narrowed aortic valve, confirmed by ultrasound tests, and who either have a history of cancer, a high risk of cancer, or kidney disease that makes them want to avoid X-rays and contrast dye. Participants will undergo the valve replacement using ultrasound guidance, which could reduce their exposure to radiation and harmful dyes. It’s important that they do not have other major heart conditions needing treatment at the same time or have already had valve replacement surgery. This study is currently recruiting patients who fit these criteria and are interested in a potentially safer option for their valve procedure.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. symptomatic severe AS determined by echocardiography and Doppler that requiring aortic valve replacement, which is defined as: mean gradient ≥40 mmHg, peak aortic velocity ≥4 m/s, and aortic valve area (AVA) ≤1 cm2 (or an indexed AVA ≤0.6 cm2/m2);
• • 2. a history of malignancy or a high familial risk of cancer, with refusal to undergo contrast- or radiation-guided procedures;
• • 3. chronic kidney disease and refuse to receive contrast agents or radiation exposure.
• Exclusion Criteria:
• • Required hybrid procedures or concomitant interventions on other cardiac malformations; Deemed inoperable due to extremely high surgical risk or severe comorbidities; Had untreated clinically significant coronary vascular disease amenable to revascularization; Previously undergone aortic valve replacement.